NO20001002D0 - Oxo-substituerte forbindelser, fremgangsmõte for fremstilling, og sammensetninger og metoder for hemming av PARP aktiviteter - Google Patents
Oxo-substituerte forbindelser, fremgangsmõte for fremstilling, og sammensetninger og metoder for hemming av PARP aktiviteterInfo
- Publication number
- NO20001002D0 NO20001002D0 NO20001002A NO20001002A NO20001002D0 NO 20001002 D0 NO20001002 D0 NO 20001002D0 NO 20001002 A NO20001002 A NO 20001002A NO 20001002 A NO20001002 A NO 20001002A NO 20001002 D0 NO20001002 D0 NO 20001002D0
- Authority
- NO
- Norway
- Prior art keywords
- methods
- oxo
- compositions
- preparation
- substituted compounds
- Prior art date
Links
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92252097A | 1997-09-03 | 1997-09-03 | |
| US7950998A | 1998-05-15 | 1998-05-15 | |
| US09/145,180 US20020022636A1 (en) | 1997-09-03 | 1998-09-01 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| PCT/US1998/018195 WO1999011624A1 (en) | 1997-09-03 | 1998-09-02 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20001002D0 true NO20001002D0 (no) | 2000-02-28 |
| NO20001002L NO20001002L (no) | 2000-04-27 |
Family
ID=27373494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20001002A NO20001002L (no) | 1997-09-03 | 2000-02-28 | Oxo-substituerte forbindelser, fremgangsmõte for fremstilling, og sammensetninger og metoder for hemming av PARP aktiviteter |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20020022636A1 (no) |
| EP (1) | EP1009739A2 (no) |
| JP (1) | JP2002512637A (no) |
| KR (1) | KR20010023909A (no) |
| CN (1) | CN1278797A (no) |
| AU (1) | AU9298698A (no) |
| BR (1) | BR9812428A (no) |
| CA (1) | CA2294118A1 (no) |
| HU (1) | HUP0004693A3 (no) |
| IL (1) | IL134847A0 (no) |
| NO (1) | NO20001002L (no) |
| PL (1) | PL339082A1 (no) |
| TR (1) | TR200001557T2 (no) |
| WO (1) | WO1999011624A1 (no) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291425B1 (en) * | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| JP2002515488A (ja) * | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法 |
| MXPA01007001A (es) | 1999-01-11 | 2002-07-30 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas. |
| EP1148053A4 (en) * | 1999-01-26 | 2002-03-06 | Ono Pharmaceutical Co | 2H-PHTHALAZIN-1-ON DERIVATIVES AND DRUG COMPOSITIONS THAT CONTAIN THESE DERIVATIVES AS ACTIVE INGREDIENTS |
| JP2001002572A (ja) * | 1999-04-19 | 2001-01-09 | Sankyo Co Ltd | ニューロトロフィン作用増強剤 |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| US6277990B1 (en) | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
| US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| AU2001264595A1 (en) * | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2001282551A1 (en) | 2000-08-31 | 2002-03-13 | Takeda Chemical Industries Ltd. | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2002044183A2 (en) | 2000-12-01 | 2002-06-06 | Guilford Pharmaceuticals Inc. | Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors |
| CA2330350A1 (en) | 2000-12-05 | 2002-06-05 | Chemokine Therapeutics Corporation | Therapeutics for chemokine mediated diseases |
| AU2002215737A1 (en) * | 2000-12-05 | 2002-06-18 | Chemokine Therapeutics Corporation | Tricyclic therapeutics for chemokine mediated diseases |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| WO2002090334A1 (en) * | 2001-05-08 | 2002-11-14 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| KR20050030636A (ko) * | 2002-07-24 | 2005-03-30 | 교린 세이야꾸 가부시키 가이샤 | 4-(치환된 아릴)-5-하이드록시이소퀴놀리논 유도체 |
| KR100735781B1 (ko) | 2002-10-01 | 2007-07-06 | 미쯔비시 웰 파마 가부시키가이샤 | 이소퀴놀린 화합물 및 그의 의약 용도 |
| EP2325224A1 (en) | 2002-10-30 | 2011-05-25 | Sumitomo Chemical Company, Limited | Aryl copolymer compounds and polymer light emitting devices made by using the same |
| ES2376166T3 (es) | 2002-11-22 | 2012-03-09 | Mitsubishi Tanabe Pharma Corporation | Compuestos de isoquinolina y su uso medicinal. |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| HU227948B1 (en) | 2003-04-30 | 2012-07-30 | Pecsi Tudomanyegyetem | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme |
| US20050008699A1 (en) * | 2003-07-11 | 2005-01-13 | Fred Wehling | Effervescent glucosamine composition |
| SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| ES2551299T3 (es) * | 2003-12-05 | 2015-11-17 | Janssen Pharmaceutica Nv | 2-Quinolinonas y 2-quinoxalinonas 6-sustituidas como inhibidores de poli(ADP-ribosa) polimerasa |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| DE102004028973A1 (de) * | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| TWI389897B (zh) | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| JP5221368B2 (ja) | 2005-11-14 | 2013-06-26 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） | Ｐａｒｐ活性のインヒビター及びその使用 |
| TWI417095B (zh) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| EP2061765B1 (en) * | 2006-09-01 | 2014-10-22 | Senhwa Biosciences, Inc. | Serine-threonine protein kinase and PARP modulators |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| EP2114948B1 (en) * | 2006-12-28 | 2014-06-25 | AbbVie Inc. | Inhibitors of poly(adp-ribose)polymerase |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| EA026578B1 (ru) * | 2007-01-22 | 2017-04-28 | ДЖиТиЭкс, ИНК. | Вещества, связывающие ядерные рецепторы |
| US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| SI2134691T1 (sl) | 2007-03-08 | 2012-06-29 | Janssen Pharmaceutica Nv | Derivati kvinolina kot PARP in TANK inhibitorji |
| MX2009011923A (es) * | 2007-05-10 | 2009-11-18 | Amr Technology Inc | Tetrahidrobenzo-1,4-diazepinas aril- y heteroaril-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina. |
| PT2200985E (pt) | 2007-09-14 | 2011-07-21 | Ortho Mcneil Janssen Pharm | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas |
| UA100126C2 (en) | 2007-09-14 | 2012-11-26 | Аддекс Фарма С.А. | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones |
| JP5433579B2 (ja) * | 2007-09-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン |
| RU2010108008A (ru) | 2007-09-14 | 2011-10-20 | Астразенека Аб (Se) | Фталазиноновые производные |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| CN101861316B (zh) * | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| AU2009289784B2 (en) | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| CN102238945B (zh) | 2008-10-07 | 2014-10-29 | 阿斯利康(英国)有限公司 | 药物制剂514 |
| WO2010045265A1 (en) * | 2008-10-13 | 2010-04-22 | Biovista, Inc. | Compositions and methods for treating multiple sclerosis |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| MX2011004957A (es) * | 2008-11-11 | 2011-08-12 | Je Il Pharmaceutical Co Ltd | Nuevo derivado triciclico o las sales farmaceuticamente aceptables del mismo, metodo de preparacion del mismo, y composicion farmaceutica que contiene el mismo. |
| TW201033226A (en) | 2008-11-28 | 2010-09-16 | Chugai Pharmaceutical Co Ltd | 1-(2h)-isoquinolone derivative |
| BRPI0921333A2 (pt) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos |
| JP5795304B2 (ja) | 2009-03-18 | 2015-10-14 | レスバーロジックス コーポレイション | 新規抗炎症剤 |
| BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| KR101753826B1 (ko) | 2009-05-12 | 2017-07-04 | 얀센 파마슈티칼즈, 인코포레이티드 | 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도 |
| AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| EP2649069B1 (en) | 2010-11-08 | 2015-08-26 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| WO2013012723A1 (en) | 2011-07-13 | 2013-01-24 | Novartis Ag | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| EP2731951B1 (en) | 2011-07-13 | 2015-08-19 | Novartis AG | 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors |
| JP5957077B2 (ja) | 2011-07-13 | 2016-07-27 | ノバルティス アーゲー | タンキラーゼ阻害剤として使用するための４−ピペリジニル化合物 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| MX2016009471A (es) | 2014-01-21 | 2016-10-13 | Janssen Pharmaceutica Nv | Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso. |
| HUE045610T2 (hu) | 2014-01-21 | 2020-01-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk |
| KR102662814B1 (ko) | 2015-03-13 | 2024-05-03 | 리스버로직스 코퍼레이션 | 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법 |
| EP3263104A1 (en) * | 2016-07-01 | 2018-01-03 | N-Gene Research Laboratories Inc. | Use of bgp15 to stimulate mitochondrial fusion |
| US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| CN106798745A (zh) * | 2016-08-31 | 2017-06-06 | 四川省人民医院 | 一种用于治疗肿瘤疾病的药物 |
| EP3534957A1 (en) | 2016-11-02 | 2019-09-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
| CN109293584B (zh) * | 2018-09-25 | 2021-11-26 | 暨南大学 | 靶向神经肽受体pac1-r的小分子别构调节化合物spam及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1880441A (en) * | 1932-10-04 | Etjbole m | ||
| US3291801A (en) * | 1963-05-23 | 1966-12-13 | Grace W R & Co | Novel octahydro-6(5)-phenanthridinones and preparation thereof |
| DE2355084A1 (de) * | 1972-11-06 | 1974-05-16 | Guidotti & C Spa Labor | Verbindungen mit magensaeuresekretionshemmender wirkung und verfahren zu deren herstellung |
| US3932643A (en) * | 1974-01-07 | 1976-01-13 | Pfizer Inc. | Phenanthridines and phenanthridinones as antiviral agents |
| SU514825A1 (ru) * | 1974-02-04 | 1976-05-25 | Химико-Фармацевтический Завод "Фармакон" | Способ получени хлоргидрата 1-фенил1-циклогексил-3-(1,-пиперидино) -пропанола-1 |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
-
1998
- 1998-09-01 US US09/145,180 patent/US20020022636A1/en not_active Abandoned
- 1998-09-02 IL IL13484798A patent/IL134847A0/xx unknown
- 1998-09-02 EP EP98945833A patent/EP1009739A2/en not_active Withdrawn
- 1998-09-02 WO PCT/US1998/018195 patent/WO1999011624A1/en not_active Application Discontinuation
- 1998-09-02 AU AU92986/98A patent/AU9298698A/en not_active Abandoned
- 1998-09-02 BR BR9812428-5A patent/BR9812428A/pt not_active IP Right Cessation
- 1998-09-02 HU HU0004693A patent/HUP0004693A3/hu unknown
- 1998-09-02 KR KR1020007002595A patent/KR20010023909A/ko not_active Application Discontinuation
- 1998-09-02 JP JP51697799A patent/JP2002512637A/ja active Pending
- 1998-09-02 CA CA002294118A patent/CA2294118A1/en not_active Abandoned
- 1998-09-02 TR TR2000/01557T patent/TR200001557T2/xx unknown
- 1998-09-02 CN CN98810936A patent/CN1278797A/zh active Pending
- 1998-09-02 PL PL98339082A patent/PL339082A1/xx unknown
-
2000
- 2000-02-28 NO NO20001002A patent/NO20001002L/no not_active Application Discontinuation
-
2002
- 2002-04-01 US US10/109,730 patent/US20030105102A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002512637A (ja) | 2002-04-23 |
| WO1999011624A1 (en) | 1999-03-11 |
| US20030105102A1 (en) | 2003-06-05 |
| NO20001002L (no) | 2000-04-27 |
| AU9298698A (en) | 1999-03-22 |
| US20020022636A1 (en) | 2002-02-21 |
| BR9812428A (pt) | 2000-09-26 |
| KR20010023909A (ko) | 2001-03-26 |
| WO1999011624B1 (en) | 1999-04-22 |
| HUP0004693A3 (en) | 2001-12-28 |
| PL339082A1 (en) | 2000-12-04 |
| HUP0004693A2 (hu) | 2001-10-28 |
| TR200001557T2 (tr) | 2001-01-22 |
| CN1278797A (zh) | 2001-01-03 |
| CA2294118A1 (en) | 1999-03-11 |
| EP1009739A2 (en) | 2000-06-21 |
| IL134847A0 (en) | 2001-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20001002D0 (no) | Oxo-substituerte forbindelser, fremgangsmõte for fremstilling, og sammensetninger og metoder for hemming av PARP aktiviteter | |
| ZA988015B (en) | Di-n-heterocyclic compounds methods and compositions for inhibiting parp activity | |
| AU9298098A (en) | Amino-substituted compounds, methods, and compositions for inhibiting parp activity | |
| ID25795A (id) | Komposisi-komposisi sampo pembentuk mousse | |
| HUP0103349A3 (en) | Phthalazine derivatives as phosphodiesterase 4 inhibitors | |
| HUP0103466A3 (en) | Substituted 1,8-naphthyridin-4(1h)-ones having phosphodiesterase 4 inhibiting activity and pharmaceutical compositions thereof | |
| NO996352D0 (no) | <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus | |
| PL338004A1 (en) | Derivatives of azetidinylpropylpiperidine, intermediate compounds and application of such derivatives as antagonists of tachykinins | |
| AU9298198A (en) | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity | |
| HK1036757A1 (en) | Sustained release oral preparations of fasudil hydrochloride | |
| HUP0103913A3 (en) | Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same | |
| ZA988018B (en) | Carboxamide compounds, methods, and compositions for inhibiting parp activity. | |
| IL139490A0 (en) | Phthalazine derivatives as phosphodiesterase 4 inhibitors | |
| DE69707659T2 (de) | Isatinderivate als acetylcholinesterase-inhibitoren und analgetika | |
| FR2776660B1 (fr) | Diazepino-indoles de phosphodiesterases iv | |
| IL145263A0 (en) | Controlled-release compositions of betahistine | |
| ID24140A (id) | Metode untuk sintesis derivatif-derivatif quinolin | |
| HK1020944A1 (en) | Substituted heterocyclic benzocycloalkenes and their use as analgesically active compounds | |
| PL337713A1 (en) | Quaternary ammonia compounds as antagonists of tachykinins | |
| EP1221963A4 (en) | METHODS OF INHIBITING OSTEOCLASTOGENESIS | |
| NO982603L (no) | FremgangsmÕte for brukerinvolvert stansing av ulovlig trÕdl°st samband | |
| ID21920A (id) | 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns | |
| FR2747308B1 (fr) | Association de margousier, de (-) hydroxycitrate et de ceramides et compositions les renfermant | |
| BR9712014A (pt) | Prepara-Æo de 1-butil-4-piperidinil metil amina | |
| AU4194500A (en) | Diastereoselective preparation of michael adducts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |